Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2023-07-10
Adverse events
3
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 45); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-12-31 (study day 156); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-15 (study day 171); relationship: not assessed; serious criteria: life-threatening
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.